Brief: Everest Medicines And Kezar Life Sciences Receive IND Approval From China NMPA For Palizade Trial In Lupus Nephritis
26/02/2024 23:12
Feb 26 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES AND KEZAR LIFE SCIENCES RECEIVE IND
APPROVAL
FROM CHINA NMPA FOR PALIZADE TRIAL IN LUPUS NEPHRITIS
Source text for Eikon: ID:nPnrjtP3a
Further company coverage: 1952.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region